» Articles » PMID: 17269711

Rapid and Noninvasive Metabonomic Characterization of Inflammatory Bowel Disease

Overview
Journal J Proteome Res
Specialty Biochemistry
Date 2007 Feb 3
PMID 17269711
Citations 230
Authors
Affiliations
Soon will be listed here.
Abstract

Inflammatory bowel diseases (IBD) including Crohn's disease (CD) and ulcerative colitis (UC) have a major impact on the health of individuals and populations. Accurate diagnosis of inflammatory bowel disease (IBD) at an early stage, and correct differentiation between Crohn's disease (CD) and ulcerative colitis (UC), is important for optimum treatment and prognosis. We present here the first characterization of fecal extracts obtained from patients with CD and UC by employing a noninvasive metabonomics approach, which combines high resolution 1H NMR spectroscopy and multivariate pattern recognition techniques. The fecal extracts of both CD and UC patients were characterized by reduced levels of butyrate, acetate, methylamine, and trimethylamine in comparison with a control population, suggesting changes in the gut microbial community. Also, elevated quantities of amino acids were present in the feces from both disease groups, implying malabsorption caused by the inflammatory disease or an element of protein losing enteropathy. Metabolic differences in fecal profiles were more marked in the CD group in comparison with the control group, indicating that the inflammation caused by CD is more extensive in comparison with UC and involves the whole intestine. Furthermore, glycerol resonances were a dominant feature of fecal spectra from patients with CD but were present in much lower intensity in the control and UC groups. This work illustrates the potential of metabonomics to generate novel noninvasive diagnostics for gastrointestinal diseases and may further our understanding of disease mechanisms.

Citing Articles

FECAL CALPROTECTIN AND INTESTINAL METABOLITES: WHAT IS THEIR IMPORTANCE IN THE ACTIVITY AND DIFFERENTIATION OF PATIENTS WITH INFLAMMATORY BOWEL DISEASES?.

Lins L, DE-Meira J, Pereira C, Crispim A, Gischewski M, Lins-Neto M Arq Bras Cir Dig. 2025; 38:e1870.

PMID: 40052996 PMC: 11870234. DOI: 10.1590/0102-6720202500001e1870.


Human-derived microRNA 21 regulates indole and L-tryptophan biosynthesis transcripts in the gut commensal .

Flanagan K, Gassner K, Lang M, Ozelyte J, Hausmann B, Crepaz D mBio. 2025; 16(3):e0392824.

PMID: 39878512 PMC: 11898669. DOI: 10.1128/mbio.03928-24.


Advancing Therapeutic Targets in IBD: Emerging Goals and Precision Medicine Approaches.

Centanni L, Cicerone C, Fanizzi F, DAmico F, Furfaro F, Zilli A Pharmaceuticals (Basel). 2025; 18(1).

PMID: 39861141 PMC: 11768140. DOI: 10.3390/ph18010078.


Advances in multi-omics integrated analysis methods based on the gut microbiome and their applications.

Duan D, Wang M, Han J, Li M, Wang Z, Zhou S Front Microbiol. 2025; 15():1509117.

PMID: 39831120 PMC: 11739165. DOI: 10.3389/fmicb.2024.1509117.


Gut microbiota mediated T cells regulation and autoimmune diseases.

Bhutta N, Xu X, Jian C, Wang Y, Liu Y, Sun J Front Microbiol. 2025; 15:1477187.

PMID: 39749132 PMC: 11694513. DOI: 10.3389/fmicb.2024.1477187.